CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance-Reference-Cited by-同舟云学术

CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance

Published:2023-02 Issue:2 Volume:41 Page:340-355.e6
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

Nilsson Monique B.,Yang Yan,Heeke Simon,Patel Sonia A.,Poteete Alissa,Udagawa Hibiki,Elamin Yasir Y.,Moran Cesar A.,Kashima Yukie,Arumugam Thiruvengadam,Yu Xiaoxing,Ren Xiaoyang,Diao Lixia,Shen Li,Wang Qi,Zhang Minying,Robichaux Jacqulyne P.,Shi Chunhua,Pfeil Allyson N.,Tran Hai,Gibbons Don L.,Bock Jason,Wang Jing,Minna John D.,Kobayashi Susumu S.,Le Xiuning,Heymach John V.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference75 articles.

1. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N. Engl. J. Med.,2009

2. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial;Rosell;Lancet Oncol.,2012

3. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR;Maemondo;N. Engl. J. Med.,2010

4. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations;Sequist;J. Clin. Oncol.,2008

5. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer;Mok;N. Engl. J. Med.,2017

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Electrochemical sensing technology based on a ligation-initiated LAMP-assisted CRISPR/Cas12a system for high-specificity detection of EGFR E746–A750 deletion mutation;Biosensors and Bioelectronics;2024-11

2. Mechanistic insights into Yifei Sanjie pill's regulation of EMT to enhance gefitinib treatment effect in NSCLC by in silico analysis and experimental validation;Journal of Ethnopharmacology;2024-11

3. Cancer therapy resistance mediated by cancer-associated fibroblast-derived extracellular vesicles: biological mechanisms to clinical significance and implications;Molecular Cancer;2024-09-07

4. Cancer drug-tolerant persister cells: from biological questions to clinical opportunities;Nature Reviews Cancer;2024-09-02

5. Drug tolerant persister cell plasticity in cancer: a revolutionary strategy for more effective anticancer therapies;Signal Transduction and Targeted Therapy;2024-08-14